肝癌患者粘附性LAK细胞制备及抗瘤活性研究  

Preparation and Anti-tumor Activity of Adherent LAK Cells from Patients with Hepatocellular Carcinoma

作　　者：柴晓杰[1] 叶胜龙[1] 吴伟忠[1] 孙瑞霞[1] 贺平[1] 汤钊猷[1] 

机构地区：[1]上海医科大学肝癌研究所,上海200032

出　　处：《中国肿瘤生物治疗杂志》1995年第3期191-193,共3页Chinese Journal of Cancer Biotherapy

基　　金：美国中华医学基金会资助课题(93-583)

摘　　要：本研究在常规LAK细胞制备基础上进行改进,用苯丙氨酸甲酯(PME)去除肝癌患者外周血中抑制LAK细胞活性的单核巨噬细胞,制备抗癌活性较高扩增迅速的粘附性LAK细胞,从实验结果分析,外周血处理后粘附性LAK细胞较未粘性LAK细胞具有较强的扩增能力,最大扩增倍数23～243倍,同时粘附性LAK细胞中T_H细胞亚群有增加趋势,T_S细胞亚群有减少趋势,其IL-2R^+表达增加至64.3％,此外,在抗瘤活性方面粘附性LAK细胞与非粘附性LAK细胞存在一定差别,分别为64.6％和42.8％,因此,从临床实用出发,制备相对高效的粘附性LAK细胞可以提高LAK疗法的治疗效果。Highly active adherent LAK cells (A-LAK) with monocytes depleted by phenylalahine methyl ester (PME) were cultured from peripheral blood lymphocytes of patients with hepatocellular carcinoma (HCC). Results showed that A-LAK cells cultured in about 14 days had expanded better and faster than that of nonadherent LAK cells (NA-LAK) with their greatest expansion varied from 23 to 243 fold .A-LAK cells showed a trend of increase in TH cell subgroup and decrease in Ts cell sub-group as well as significant difference of TH/TS ratio. The IL-2R expression increased from 34.1%to 64.3%. A-LAK cells had a higher cytotoxicity (64.6%)than that of NA-LAK cells (42.8%).Further clinical application of A-LAK cells may improve biotherapeutic effect on HCC patients compared with that of NA-LAK cells .

关 键 词：LAK细胞 肝癌患者 抗瘤活性 扩增 外周血 粘附性 细胞亚群 制备 甲酯 研究 

分 类 号：R392[医药卫生—免疫学] R730[医药卫生—基础医学]